Professor Paul Workman FRS FMedSci FRSC is a multidisciplinary cancer research scientist, molecular pharmacologist and chemical biologist who has been responsible for the laboratory discovery of chemical probes and innovative cancer drugs. His specialty is designing personalized cancer medicines that are targeted to precise molecular abnormalities and vulnerabilities – an approach he refers to as ‘drugging the cancer genome’. Paul is particularly well known for the discovery of clinical drug candidates and chemical probes inhibiting protein kinases, PI3 kinases, the molecular chaperone HSP90 and recently the HSF1 pathway. He is Harrap Professor of Pharmacology and Therapeutics at The Institute of Cancer Research, London (ICR) and was previously Chief Executive and President, Deputy CEO and Director of the CRUK Cancer Therapeutics Unit at ICR. Paul is committed to the development and best practice use of chemical probes in biomedical research and serves as Executive Director of the Chemical Probes Portal. He has also overseen a sequential series of guidelines for the welfare and use of animals in cancer research and currently chairs a working group that aims to publish new best practice guidelines in 2022.